ERCC1 Antibody

What is ERCC1 and why is it important in cancer research?

ERCC1 is a mammalian nucleotide excision repair (NER) enzyme involved in repairing damaged DNA. It is encoded by the ERCC1 gene located on chromosome 19 and forms a heterodimer with XPF to create a structure-specific endonuclease essential for DNA repair . This complex plays a critical role in several DNA repair pathways, including nucleotide excision repair and interstrand crosslink repair.

ERCC1 has gained significant attention in cancer research because high expression levels have been linked to tumor progression in multiple cancers including non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head, ovarian cancer, and esophageal cancer . More importantly, increased levels of ERCC1 expression may correlate with lower response to platinum-based chemotherapies, making it a potential predictive biomarker for treatment selection .

What are the key isoforms of ERCC1 and which are functionally significant?

Four distinct ERCC1 isoforms arising from alternative splicing have been described (201, 202, 203, and 204), but only the 202 isoform is functional in DNA excision repair when interacting with its obligate partner XPF . The 204 isoform notably lacks the exon 3 coding region, which impacts its functionality .

This differential functionality creates significant challenges for researchers, as detecting specifically the functional ERCC1-202 isoform is difficult due to high sequence homology between the four isoforms. Understanding which isoform is being detected is critical for accurate interpretation of research findings and potential clinical applications.

How do researchers typically detect ERCC1 expression in tissue samples?

The standard method for evaluating ERCC1 protein expression in tissue samples is immunohistochemistry (IHC). In IHC procedures, researchers typically:

• Process formalin-fixed, paraffin-embedded tissue sections

• Apply a specific anti-ERCC1 primary antibody

• Visualize binding using secondary antibodies and detection systems

• Score expression levels using a standardized scoring system

For example, a commonly used scoring system categorizes ERCC1 expression on a scale from 0-3:

Western blotting, immunoprecipitation, immunofluorescence, and enzyme-linked immunosorbent assays (ELISA) are also utilized depending on the research context . For more precise quantitative analysis, RT-PCR techniques can be employed to measure ERCC1 mRNA levels, although protein expression is generally considered more directly relevant to function .

What are the key challenges in antibody specificity for ERCC1 detection?

A significant challenge in ERCC1 research has been antibody specificity. The 8F1 clone, which was widely used in early studies, was later found to cross-react with at least one unrelated protein (PCYT1A), raising concerns about the reliability of associated research findings .

This specificity issue is particularly problematic because:

• It compromises the validity of published studies using non-specific antibodies

• It creates uncertainty in correlations between ERCC1 expression and clinical outcomes

• It complicates the use of ERCC1 as a biomarker for treatment selection

To address specificity concerns, researchers should implement a three-pronged validation approach:

• Test for size and location specificity via immunoblots using positive and negative controls

• Conduct immunoprecipitation studies to confirm identity

• Validate with immunohistochemistry on cell lines with known ERCC1 expression levels

Several newer antibodies have been developed with improved specificity, including the 4F9 clone, which has shown superior performance in multiple validation studies .

How can researchers specifically detect the functional ERCC1-202 isoform?

Detecting specifically the functional ERCC1-202 isoform presents unique challenges due to high sequence homology between isoforms. A breakthrough methodology involves the use of proximity ligation assay (PLA) technology combined with specific antibodies:

• Generate monoclonal antibodies directed against the ERCC1-XPF heterodimer (such as 2C11, 7C3, and 10D10)

• Combine one heterodimer-specific antibody with a commercial anti-ERCC1 antibody (clone 4F9) in a proximity ligation assay

• The 4F9 clone is unable to recognize the 204 isoform, creating specificity when used in combination

This methodology specifically detects the functional ERCC1-202 isoform by recognizing both the heterodimer formation and isoform-specific characteristics . This approach represents a significant advancement for studies investigating the relationship between functional ERCC1 expression and clinical outcomes.

What approaches help address interobserver variability when scoring ERCC1 expression?

Interobserver variability represents a significant challenge in ERCC1 expression analysis. In one study, two observers initially agreed on only 80.3% of cases (weighted kappa = 0.75, 95% CI: 0.66–0.84) . To improve consistency, researchers should:

• Implement standardized scoring systems with clear definitions

• Use internal reference tissues for calibration

• Employ multiple trained observers and resolve discrepancies through consensus

• Consider automated image analysis systems to supplement manual scoring

How does ERCC1 deficiency affect cellular responses to DNA-damaging agents?

ERCC1-deficient cells show dramatically increased sensitivity to various DNA-damaging agents, particularly:

• Platinum compounds (cisplatin, carboplatin)

• Lipid peroxidation (LPO) products including 4-hydroxy-2-nonenal (HNE), crotonaldehyde, and malondialdehyde

• UV radiation

• DNA crosslinking agents

In mechanistic studies with HNE (a major endogenous LPO product), ERCC1-deficient cells exhibited:

• Inhibited proliferation

• Stimulated ROS and LPO formation

• Induced DNA base damage and strand breaks

• Increased error-prone translesion DNA synthesis

• Enhanced cellular senescence

• Deregulated base excision repair and energy production pathways

These findings highlight the critical role of ERCC1 in protecting cells against various types of DNA damage and suggest that ERCC1 deficiency can sensitize cells to both endogenous and exogenous DNA-damaging agents.

What technical considerations are important when developing experimental models for ERCC1 research?

When developing experimental models for ERCC1 research, several technical considerations are critical:

What are the comparative advantages and limitations of different anti-ERCC1 antibodies?

Several anti-ERCC1 antibodies have been developed, each with distinct characteristics:

When selecting an antibody, researchers should consider:

• The specific isoforms they need to detect

• Whether monomeric ERCC1 or the ERCC1-XPF complex is of interest

• The application (IHC, WB, IP, etc.)

• The requirement for validated specificity

The development of the 4F9 clone has addressed many of the specificity concerns associated with earlier antibodies, making it a preferred choice for many current research applications.

What protocol optimizations are recommended for successful ERCC1 immunohistochemistry?

For optimal ERCC1 immunohistochemistry results, researchers should consider:

• Tissue fixation: Extensive fixation can lead to weak staining. In one study, staining was too weak in 8.5% of samples, indicative of extensive fixation . Standardize fixation time and conditions across samples.

• Internal references: Include internal reference tissues (tonsil, testis, breast, prostate, fallopian tube are recommended controls) . Internal references were absent in 6.4% of samples in one study .

• Antibody selection: Use validated antibodies with demonstrated specificity, such as the 4F9 clone, which has shown superior performance in validation studies .

• Scoring system calibration: Before scoring study samples, establish consensus on scoring criteria using a training set of specimens.

• Tumor heterogeneity consideration: ERCC1 expression can vary within a tumor. In one study, tumor heterogeneity was observed in 17.5% of specimens . Multiple sampling from different tumor regions may be necessary.

• Centrifugation for concentrated antibodies: For concentrated antibodies, centrifugation prior to use ensures recovery of all product .

By implementing these optimizations, researchers can improve the reliability and reproducibility of ERCC1 immunohistochemistry results.

How can researchers validate the correlation between ERCC1 expression and platinum treatment response?

To validate correlations between ERCC1 expression and platinum treatment response, researchers should employ a multi-faceted approach:

• Retrospective analysis with rigorous controls:

  • Analyze cohorts of patients with well-documented treatment histories

  • Include patients treated with and without platinum agents

  • Control for confounding variables (disease stage, other treatments)

• Prospective studies with standardized protocols:

  • Define ERCC1 assessment method and cutoff values a priori

  • Stratify patients based on ERCC1 status

  • Document treatment response using RECIST criteria or similar standardized metrics

• Functional validation in experimental models:

  • Establish cell lines with varied ERCC1 expression levels

  • Confirm ERCC1 function through DNA repair capacity assays

  • Test platinum sensitivity in vitro and in xenograft models

• Comprehensive ERCC1 characterization:

  • Assess both protein expression and functional activity

  • Specifically detect the functional ERCC1-202 isoform

  • Consider heterodimer formation with XPF

What emerging technologies are advancing ERCC1 detection and functional analysis?

Several emerging technologies are improving ERCC1 detection and functional analysis:

• Proximity Ligation Assay (PLA):

  • Combines heterodimer-specific antibodies with isoform-specific antibodies

  • Allows specific detection of functional ERCC1-202/XPF complexes

  • Superior specificity compared to conventional IHC

• Genetic Immunization:

  • Novel approach for generating antibodies against protein complexes

  • Produced monoclonal antibodies (2C11, 7C3, 10D10) that specifically recognize the ERCC1-XPF heterodimer

  • Enables detection of functionally relevant protein complexes rather than single proteins

• Multiplex Immunofluorescence:

  • Allows simultaneous detection of ERCC1 with other DNA repair proteins

  • Enables assessment of co-localization and potential functional interactions

  • Provides spatial context within the tumor microenvironment

• CRISPR/Cas9 Gene Editing:

  • Creation of isogenic cell lines with defined ERCC1 mutations or isoform expression

  • Allows precise assessment of specific ERCC1 variants on cellular function

  • Enables mechanistic studies of ERCC1 in DNA repair pathways

These technologies are providing researchers with more precise tools to study ERCC1 expression, localization, and function, which will likely lead to improved understanding of its role in cancer biology and treatment response.

How do ERCC1 mutations impact human health and DNA repair capacity?

ERCC1 mutations in humans can result in severe phenotypes characterized by:

• Short stature

• Photosensitivity

• Progressive liver and kidney dysfunction

• Features consistent with Cockayne Syndrome (CS)

Molecularly, these mutations impact DNA repair through several mechanisms:

• Protein instability: Mutations such as R156W dramatically reduce protein levels of both ERCC1 and XPF .

• Impaired protein interactions: Mutant ERCC1 shows weakened interactions with NER and ICL repair proteins, resulting in diminished recruitment to DNA damage sites .

• Reduced repair activity: Patient cells show strongly reduced NER activity and increased chromosome breakage induced by DNA cross-linkers .

Interestingly, while NER and ICL repair are significantly impacted, DSB repair remains relatively normal in some ERCC1-deficient patients . This selective impairment of specific DNA repair pathways explains the unique constellation of symptoms observed in affected individuals.

What is the role of ERCC1 in aging and how do animal models inform our understanding?

ERCC1 plays a crucial role in aging processes, as evidenced by animal models:

• Progeria-like phenotypes in knockout models: ERCC1-deficient mice exhibit numerous progeroid symptoms affecting the hepatobiliary, renal, ocular, neurological, hematopoietic, musculoskeletal, epidermal, and endocrine systems .

• Differential lifespan effects: Complete knockout mice (Ercc1−/−) live only about four weeks, while hypomorphic mutants (Ercc1−/Δ) expressing ~5% of normal ERCC1-XPF have a lifespan of 7 months .

• Lipid peroxidation sensitivity: ERCC1-deficient cells and mice are hypersensitive to lipid peroxidation (LPO) products and LPO inducers:

  • Cells show increased sensitivity to HNE, crotonaldehyde, and malondialdehyde

  • Mice exposed to CCl₄ (an LPO inducer) or a diet rich in polyunsaturated fatty acids show accelerated aging-related pathologies

• Vascular aging: Endothelial-specific ERCC1 knockout mice display:

  • Increased senescence-associated secretory phenotype expression

  • Reduced blood-brain barrier integrity

  • Higher endothelial sprouting capacities due to dysregulated Dll4-Notch pathway

  • Blood-brain barrier leakage and enhanced immune cell infiltration into the brain

These findings suggest that ERCC1's DNA repair function is essential for maintaining tissue homeostasis during aging, and that accumulated DNA damage due to ERCC1 deficiency accelerates aging phenotypes.

What strategies can improve reproducibility in ERCC1 biomarker studies?

To improve reproducibility in ERCC1 biomarker studies, researchers should implement:

• Standardized antibody validation:

  • Document specificity testing for size, location, and identity

  • Include positive and negative controls in all experiments

  • Report the specific clone and lot number of antibodies used

• Transparent methodological reporting:

  • Provide detailed protocols for tissue processing, staining, and scoring

  • Report interobserver agreement statistics

  • Document handling of heterogeneous staining patterns

• Isoform-specific detection:

  • Specify which ERCC1 isoforms are detected by the selected antibody

  • Consider methods to specifically detect the functional ERCC1-202 isoform

  • Validate correlation between detected isoforms and functional outcomes

• Multi-institutional validation:

  • Test biomarker performance across different laboratories

  • Use identical protocols and reagents

  • Include centralized review of scoring

• Integration with other biomarkers:

  • Combine ERCC1 assessment with other DNA repair markers

  • Correlate protein expression with mRNA levels and genetic alterations

  • Develop integrated biomarker panels for improved predictive power